Industry Insights

1. Breaking Through Tumor Defenses With Next-Generation Cell Therapy 2/20/2026

   Ernexa Therapeutics CEO Sanjeev Luther shares how clinical research has revealed why certain cancers resist treatment and how emerging cell therapies may help break through those defenses.

2. MES Is Still In The CD ROM Era But The Data Architecture Has Moved On 2/20/2026

   Many manufacturing execution system (MES) deployments still operate like it is 2005: a big install, disruptive upgrades, etc. Here's a clearer path forward.

3. Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real 2/18/2026

   Mesoblast's Silviu Itescu shares how two decades of rigorous science and manufacturing turned allogeneic MSCs into the first FDA-approved cell therapy while building a scalable platform for inflammatory diseases such as GvHD, back pain, and heart failure.

4. U.S. Pharma Tariffs And MFN In 2026: Manufacturing And Procurement Impact 2/18/2026

   Beroe Inc.'s Mathini Ilancheran discusses the 2025 U.S. pharma tariff framework and translates it into actionable procurement and outsourcing responses.

5. Active Versus Passive Shipping Solutions For Clinical Shipments 2/13/2026

   Explore active and passive temperature-controlled shipping solutions and their impact on clinical trial supply, balancing cost, risk, and product integrity.

6. January 2026 — CDMO Opportunities And Threats Report 2/12/2026

   Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

7. Why In Vivo Therapies Fail When We Treat Them Like Ex Vivo Ones 2/9/2026

   For the next-generation cell and gene therapies, we must rethink design and controls, and we must reframe the problem from modality to architecture.

8. Leveraging Conventional Therapeutics Skills For Cell And Gene Therapy 2/6/2026

   Cell and gene therapies share fundamental objectives with conventional biologics. Their common challenges offer a natural starting point to solving downstream bottlenecks.

9. Why Clinical Supply Risk Starts With Demand Signals 2/5/2026

   Clinical supply risk often begins long before manufacturing or distribution. Flawed demand signals and enrollment forecasts can quietly create shortages, delays, and costly material waste.

10. A Year Of Separation: Which Advanced Modalities Are Built For Commercial Scale In 2026? 1/30/2026

    In 2026, advanced therapies diverge: winners pair proven biology with scalable manufacturing, delivery, and workflow fit, while others advance more slowly under operational and economic limits.